See more : Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Satellos Bioscience Inc. (MSCL.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Satellos Bioscience Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shinsung Tongsang Co., Ltd. (005390.KS) Income Statement Analysis – Financial Results
- Idera Pharmaceuticals, Inc. (IDRA) Income Statement Analysis – Financial Results
- PepsiCo, Inc. (PEP.DE) Income Statement Analysis – Financial Results
- East Buildtech Limited (EASTBUILD.BO) Income Statement Analysis – Financial Results
- PT Indointernet Tbk. (EDGE.JK) Income Statement Analysis – Financial Results
Satellos Bioscience Inc. (MSCL.V)
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 336.95K | 119.92K | 48.16K | 3.06K |
| Gross Profit | -336.95K | -119.92K | -48.16K | -3.06K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.59M | 1.88M | 892.78K | 917.48K |
| General & Administrative | 5.44M | 2.60M | 904.97K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.44M | 2.60M | 904.97K | 1.29M |
| Other Expenses | -48.67K | -84.44K | -75.01K | 0.00 |
| Operating Expenses | 8.38M | 4.54M | 1.43M | 2.20M |
| Cost & Expenses | 8.38M | 4.66M | 1.48M | 2.21M |
| Interest Income | 20.63K | 7.99K | 4.97K | 0.00 |
| Interest Expense | 0.00 | 985.33K | 23.05K | 0.00 |
| Depreciation & Amortization | 336.95K | 165.69K | 422.00 | -3.06K |
| EBITDA | -8.07M | -4.57M | -1.54M | -2.20M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.41M | -4.74M | -1.55M | -2.21M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.89M | -10.65M | 349.79K | 2.64K |
| Income Before Tax | -11.32M | -15.51M | -1.58M | -2.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.62K | 900.90K | -51.96K | -264.79K |
| Net Income | -11.32M | -15.51M | -1.58M | -1.94M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.32 | -0.64 | -0.05 | -0.32 |
| EPS Diluted | -0.32 | -0.64 | -0.05 | -0.32 |
| Weighted Avg Shares Out | 35.68M | 24.08M | 32.87M | 6.12M |
| Weighted Avg Shares Out (Dil) | 35.68M | 24.08M | 32.87M | 6.12M |
Source: https://incomestatements.info
Category: Stock Reports